MRKMerck Sharp & Dohme LLCRunning, no new patients
Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)
Genital Warts
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 1,590 (planned)
- Started
- May 7, 2022
- Main results expected
- Feb 19, 2029
- Fully finished
- Feb 19, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Competitive Luminex immunoassay (cLIA) GMTs to 9 vaccine types of 9vHPV vaccine at one month post last dose
Measured over: Up to Month 13
cLIA GMTs to 9 vaccine types of 9vHPV vaccine up to 60 months post last dose
Measured over: Up to 72 months
cLIA seropositivity percentages to 9 vaccine types of 9vHPV vaccine
Measured over: Up to 72 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05314023 · record last updated 2023-01-19 · checked 2026-11-09 15:47 UTC